Eli Lilly tops $1 trillion as Novo Nordisk eats the losses of a drug war
Eli Lilly's market value surpassed $1 trillion, driven by strong sales of obesity drugs Mounjaro and Zepbound, with Q3 revenue up 39% to $24.4 billion. Novo Nordisk faces pricing pressure and expects lower earnings, with shares down 20% over a year. Lilly's market cap reached $1.26 trillion, while Novo's fell after a February warning. Both companies are competing in the obesity drug market, with Lilly gaining market share.
How this was made
The 30-second read
Why it matters
Lilly's guidance raise may attract growth‑oriented capital, while Novo's outlook could trigger defensive positioning.
Market read
The contrasting earnings outcomes create a clear trade narrative between the two sector leaders.
What to watch
Potential regulatory changes to obesity‑drug pricing and insurance coverage could alter the competitive landscape.
Background
The article compares the divergent trajectories of the two leading GLP‑1 drug makers after Lilly's Q3 earnings and guidance lift versus Novo's earlier warning.
Ticker impact
Eli Lilly reported Q3 revenue of $24.4B, raised full-year 2026 guidance by $5.5B and its shares jumped 6.6% after the release.
likely upward pressure as the market prices in higher revenue expectations
The new guidance and record sales for Mounjaro and Zepbound signal continued growth, supporting a bullish stance.
Novo Nordisk disclosed a February warning that 2026 sales and profit could fall 5‑13%, causing a $50B market‑value loss and a 20% 12‑month decline.
likely pressure as investors digest lower‑growth outlook
The guidance cut and pricing pressure suggest further weakness unless upcoming results beat expectations.
Market effects
Obesity‑drug market dynamics may shift investor focus toward companies with lower‑cost oral GLP‑1 options.
U.S. healthcare sector gains from Lilly's beat; European peers like Novo face valuation pressure.
The trillion‑dollar valuation milestone highlights the growing importance of metabolic therapies worldwide.
Counterpoint
If Novo's pricing pressure eases and Wegovy sales rebound, the stock could recover faster than implied.
Key entities
- CompanyEli Lilly
U.S. pharmaceutical company leading in obesity and diabetes drugs.
- CompanyNovo Nordisk
Danish pharmaceutical firm competing in the GLP‑1 market.
